Matthew Byerly, M.D.
Dr. Byerly’s research focuses on two areas. He has had a long-standing interest in improving treatments for those with schizophrenia, having served on multiple expert panels related to antipsychotic treatments and as a member of the Food and Drug Administration Psychopharmacologic Drugs Advisory Committee. He has studied the extent, correlates, and consequences of medication non-adherence, as well as methods to improve medication adherence. This work led to the development of the Brief Adherence Rating Scale, a leading scale of medication adherence assessment. He is currently linking improved medication adherence assessment methods with adherence interventions to determine if such approaches can reduce the symptoms and enhance the functioning of those with schizophrenia.
In 2012, Dr. Byerly joined the UT Southwestern Center for Autism and Developmental Disabilities (CADD), extending his research interest to studying potential pharmacologic treatments for neurodevelopmental disorders. He and colleagues are working to translate recent advances in the treatment of mouse models of fragile X syndrome and Down syndrome to individuals affected by these conditions. Dr. Byerly has also established the Adult Fragile X Syndrome Psychopharmacology Clinic where he offers the very latest in medication treatments for this condition.
|Medical School||University of Arizona College of Med. (1990)|
McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS JAMA 2014 May 311 19 1978-87
Neurophysiological Correlates of Sensory Hypersensitivities in ASD and Fragile X Syndrome
Ethridge, L.E., White, S.P., Mosconi, M.W., Wang, J., Greene, R., Soilleux, M., Bylery, M.J., Sweeney, J.A. 2014
Byerly MJ, Nakonezny PA, Rush AJ Schizophr. Res. 2008 Mar 100 1-3 60-9
Byerly MJ, Nakonezny PA, Lescouflair E Psychiatr. Clin. North Am. 2007 Sep 30 3 437-52
Byerly MJ, Thompson A, Carmody T, Bugno R, Erwin T, Kashner M, Rush AJ Psychiatr Serv 2007 Jun 58 6 844-7